Introduction {#acn3279-sec-0001}
============

Progressive multifocal leukoencephalopathy (PML) is a destructive demyelinating disease of the central nervous system caused by the John Cunningham virus (JCV), which belongs to the family of polyoma viruses. The onset of the disease is subacute, with a broad range of clinical features. Its course is progressive and often fatal.[1](#acn3279-bib-0001){ref-type="ref"} Carriership of JCV is common among healthy individuals and it remains latent in the kidney, lymphoreticular, or brain tissue. Approximately 70% of adults are seropositive for JCV. Reactivation of the virus, resulting in PML, occurs typically under immunosuppressive conditions.[1](#acn3279-bib-0001){ref-type="ref"} The growing number of immunosuppressive and immunomodulatory therapeutics has resulted into an increased number of individuals at risk for PML.[2](#acn3279-bib-0002){ref-type="ref"} Although the common denominator in all these conditions is suppression of cellular immunity (either iatrogenic or endogenous), PML may also occur in patients with minimal or occult immune suppression (e.g., idiopathic CD4+ lymphocytopenia, chronic kidney, or liver disease)[3](#acn3279-bib-0003){ref-type="ref"} and even occasionally in apparently immunocompetent patients.[4](#acn3279-bib-0004){ref-type="ref"} Here, we present a case of PML in an apparently immunocompetent patient in whom a deficit of the interferon *γ* (IFN*γ*) pathway, and compound heterozygozity for mutations in BCL2‐associated athanogene 3 (*BAG3*) were identified.

Patient and Methods {#acn3279-sec-0002}
===================

A 49‐year‐old Caucasian male presented with rapidly progressive symptoms of aphasia, dyscalculia, hyperesthesia of the right arm, and headache. Two months after the first symptoms, his clinical condition worsened acutely with an inability to speak and to carry out activities of daily living, apraxia, confusion, and severe headache. His vital signs were normal and neurologic examination confirmed a nonfluent aphasia, dysgraphia, mild facial paresis on the right, a right‐sided hemianopsia, hemi‐hypaesthesia, and hyperreflexia without extensor plantar responses. He used no medication and had no significant medical history. The family history was unremarkable for neurologic conditions. Laboratory tests showed normal leukocyte counts, including CD3, CD4, and CD8 counts (ratio T4/T8), low infectious parameters, negative serology for human immunodeficiency virus (HIV), Lues, Borrelia, and Herpes Simplex Virus (HSV). Cerebrospinal fluid (CSF) analysis showed normal cell counts, protein and glucose levels, no oligoclonal bands or markers of neurodegeneration (except for a slightly elevated Tau \[431 ng/L\], normal \<300 ng/L), and cytological analysis showed no signs of malignancy. Cerebral MRI showed confluating subcortical white matter T2 hyperintensities predominantly in the left hemisphere, which extended on consecutive MRIs without contrast enhancement or mass effect (Fig. [1](#acn3279-fig-0001){ref-type="fig"}). PCR for JCV in serum and CSF was negative.

![MRI images 4 months after first presentation. (A) Fluid‐attenuated inversion recovery (FLAIR) MRI: large confluating asymmetric white matter hyperintensities lesions in the frontal and parietal lobes. (B) T1‐gadolinium sequences without contract enhancement.](ACN3-3-226-g001){#acn3279-fig-0001}

A stereotactic biopsy of the left frontal lobe showed perivascular lymphocytic infiltration with sporadic enlarged nuclei, which resembled astrocytes. No pathologic oligodendrocyte nuclei were found and immunohistochemical staining for SV‐40 (polyomavirus) was negative. However, a positive PCR alone is no confirmation of active virus replication. The PCR for JCV on the biopsy material, however, was positive. The normal immune status and the lack of evidence for an active JCV infection led to the primary diagnosis of tumefactive multiple sclerosis, and the patient was treated consecutively with methylprednisolone intravenously, glatiramer acetate (20 mg/mL once daily), acetaminophen (1000 mg four times a day), and plasmapheresis.[5](#acn3279-bib-0005){ref-type="ref"} As deterioration continued the biopsy material was re‐examined 7 months after symptom onset, in a tertiary center with extensive expertise on PML. The presence of foam cells, some bizarre astrocytes, and sporadic oligodendrocytes with ground glass appearance combined with the clinical course led to a revision of the diagnosis to PML, and the patient was started on mirtazapine (15 mg once daily). Unfortunately his condition was progressive and he died 9 months after the initial presentation due to cardiopulmonary complications of a bilateral pneumonia. Autopsy confirmed the diagnosis of PML. Macroscopy showed extensive white matter hyperintensities in both hemispheres, with focal gray glass lesions, suggestive for PML. Microscopy showed large white matter hyperintensities with prominent demyelination, and a granular tissue loss. Extensive reactive astrocytosis, and astrocytes with enlarged polymorph hyperchromatic nuclei were found, indicating a viral cytopathogenic effect. A few oligodendrocytes with enlarged nuclei, perivascular foamy macrophages, and some lymphocytic infiltration were seen.

Immunological assessment {#acn3279-sec-0003}
------------------------

After the diagnosis of PML an assessment of the capacity of cells isolated from the patient to respond to microbial stimuli was initiated. Peripheral blood mononuclear cells were isolated from blood collected from the patient, and stimulated with the TLR4‐ligand lipopolysaccharide (*Escherichia coli* LPS 10 ng/mL), the TLR3‐ligand PolyI:C (5 *μ*g/mL), and a fungal stimulus (heat‐killed *Candida albicans* 10^5^ microorganisms/mL). IFN*γ* production capacity was measured using an enzyme‐linked immunosorbent assay.

Genetic analysis {#acn3279-sec-0004}
----------------

Whole exome sequencing was performed as described earlier.[6](#acn3279-bib-0006){ref-type="ref"}, [7](#acn3279-bib-0007){ref-type="ref"} In brief, DNA was isolated from whole blood, enriched with SureSelect v2 exome (Agilent Technologies, Santa Clara, CA) (50 Mb) and sequenced on SOLiD 4 (Life Technologies, Foster City, CA). Variants were called using high stringency settings and annotated with an in‐house pipeline containing information from dbSNP134. Variant filtering was applied as previously reported; in brief, we only selected variants affecting coding exons, microRNAs, and canonical splice sites. Subsequently, synonymous variants were filtered out, and only rare variants (frequency of \<0.25% in both dbSNP134 and our in‐house database containing \>2000 exomes) with high quality were reported (Table [1](#acn3279-tbl-0001){ref-type="table-wrap"}). All genes with rare nonsynonymous variants were systematically checked for involvement role in immunity; based on Gene Ontology terms, mouse knockout phenotypes, information from the Kyoto Encyclopedia of Genes and Genomes or direct interaction with JCV according to NCBI (the latter was performed by searching for JCV in NCBI, and selecting for genes in humans).

###### 

Exome sequencing statistics and the filter settings applied to exclude noncoding, nonsynonymous, common, and low‐quality variants

  Sample                                       PML patient
  -------------------------------------------- -----------------------------
  Total mapped bases (Gb)                      5.5
  On and near target (%)                       82.0%
  Median fold coverage                         57.6
  Average fold coverage                        81.7
  \% Covered \>onefold                         94.1%
  \% Covered \>10‐fold                         82.8%
  \% Covered \>20‐fold                         74.5%
  Total variants                               35,322
  Coding, canonical, microRNA                  14,595
  Nonsynonymous                                7211
  Rare variants \<0.25% SNP, in‐house exomes   188
  Variant reads \>5% and \>25%                 106
  Variants in immune‐related pathways          21
  Associated with JCV (NCBI)                   2 variants, 1 gene (*BAG3*)

PML, progressive multifocal leukoencephalopathy; *BAG3*, BCL2‐associated athanogene 3; JCV, John Cunningham virus.

John Wiley & Sons, Ltd

Results {#acn3279-sec-0005}
=======

Immunological assessment {#acn3279-sec-0006}
------------------------

While cytokine production upon stimulation with LPS and *C. albicans* was normal compared to eight healthy individuals. IFN*γ* production induced by PolyI:C was severely impaired in the patient versus control stimulation (Fig. [2](#acn3279-fig-0002){ref-type="fig"}). We were unable to perform extensive immunophenotyping of T‐, B‐, and NK‐cell subpopulations as our patient deceased shortly after the diagnosis of PML.

![Interferon *γ* (IFN *γ*) production capacity was measured in the progressive multifocal leukoencephalopathy (PML) patient and compared with eight healthy controls upon stimulation with the TLR3 ligand PolyI:C (5 *μ*g/mL) (left) and *Candida albicans* (1 × 10^5^ microorganisms/mL) (right). The PML patient showed a clear defect in IFN *γ* production upon PolyI:C stimulation compared to controls, whereas stimulation with *Candida* does not result in significant differences.](ACN3-3-226-g002){#acn3279-fig-0002}

Genetic analysis {#acn3279-sec-0007}
----------------

Whole exome sequencing provided 5.5 Gb of mapped sequencing data, resulting in an average coverage of the exome of 81.7‐fold. Standard variant filtering resulted in 106 rare, nonsynonymous, and canonical splice site variants. Only 17 genetic variants remained after filtering for genes with a possible role in immunity (Table [2](#acn3279-tbl-0002){ref-type="table-wrap"}). A genome‐wide search in NCBI for genes associated with JCV interaction resulted in 21 genes. An overlap between these 21 genes, and the 106 rare variants resulted in one gene for which JCV interaction was described earlier[8](#acn3279-bib-0008){ref-type="ref"}, [9](#acn3279-bib-0009){ref-type="ref"}; we found two very rare heterozygous variants in exon 2 of the *BAG3*. Cosegregation analysis within the family shows that both unaffected parents carry one of the variants in a heterozygous state, and both variants are absent in the healthy brother (Fig. [3](#acn3279-fig-0003){ref-type="fig"}). The variants (p. P77L; p.I94F) have been reported at population allele frequencies of 0.029% and 0.076%, respectively. In addition, rare (\<1%) homozygous protein‐altering variants are only reported in 16 of \>60,000 controls.[10](#acn3279-bib-0010){ref-type="ref"}

###### 

Seventeen rare variants with association to immune system for the respective genes

  Selection criteria   Gene name   Gene component      mRNA change   Amino acid change   ExAC allele frequency   ExAC \# of alleles/total   SIFT prediction   Polyphen prediction   PhyloP\*   Grantham score
  -------------------- ----------- ------------------- ------------- ------------------- ----------------------- -------------------------- ----------------- --------------------- ---------- ----------------
  A(2), B              *BAG3*      Exon                230C\>T       p.P77L              0.0002883               35/121,382                 Tolerated         Benign                −0.157     98
  A(2), B              *BAG3*      Exon                280A\>T       p.I94F              0.000758                92/121,376                 Deleterious       Probably damaging     2.098      21
  B                    *CDC73*     Exon                685A\>G       p.R229G             0                       0                          Deleterious       Probably damaging     2.305      125
  B                    *TP53BP2*   Exon                808T\>C       p.M399V             0.000239                29/121,318                 Tolerated         Benign                2.459      21
  B                    *CPN1*      Exon                166C\>A       p.E56X              0                       0                          N/A               N/A                   0.354      1000
  B                    *KDM5A*     Exon                1885C\>T      p.V629M             0.00002485              3/120,732                  Deleterious       Possibly damaging     4.234      21
  B                    *HYDIN*     Exon                2804T\>C      p.N935S             0                       0                          Not scored        Probably damaging     4.186      46
  B                    *CBFA2T2*   Exon                757G\>A       p.G282S             0.000008237             1/121,404                  Tolerated         Benign                1.669      56
  B                    *NIPBL*     Exon                3851A\>G      p.N1284S            0.00002486              3/120,678                  Deleterious       Benign                2.76       46
  B                    *CALCR*     Exon                396T\>G       p.E132D             0                       0                          Deleterious       Benign                0.02       45
  B                    *ATP7A*     Exon                3107A\>G      p.H1036R            0                       0                          Deleterious       Probably damaging     4.925      29
  B, D                 *AHNAK*     Exon                16255C\>T     p.D5419N            0.0004119               50/121,374                 Deleterious       Probably damaging     0.387      23
  B, E, F              *ITGA4*     Exon                722A\>G       p.K241R             0                       0                          Tolerated         Benign                −3.015     26
  C                    *IFI16*     Exon                494G\>A       p.R165H             0.0001236               15/121,400                 Tolerated         Benign                −3.32      29
  D                    *KYNU*      Exon                1303G\>A      p.V435M             0                       0                          Deleterious       Probably damaging     3.041      21
  E                    *ARRB1*     Canonical SA site   N/A           N/A                 0.000008239             1/121,376                  N/A               N/A                   5.068      0
  F                    *LAMB3*     Exon                2632G\>A      p.R878C             0.00005767              7/121,396                  Deleterious       Probably damaging     1.177      180

*BAG3*, BCL2‐associated athanogene 3; JCV, John Cunningham virus. A, NCBI human gene name interaction with JCV and number of PubMed publications (N); B, mouse knockout phenotype "immune"; C, Gene Ontology term "virus"; D, Gene Ontology term "interferon"; E, Kyoto Encyclopedia of Genes and Genomes class "immune"; F, Kyoto Encyclopedia of Genes and Genomes class "infectious." PhyloP\* relates to the amino acid conservation among 46 species. ExAC (Exome Aggregation Consortium[10](#acn3279-bib-0010){ref-type="ref"}).
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![Family pedigree of our progressive multifocal leukoencephalopathy (PML) case; the unaffected parents were both carrier of one rare BCL2‐associated athanogene 3 (*BAG3*) variant (paternal variant p.P77L, c.230C\>T; maternal variants p.I94F, c.280A\>T). The compound heterozygosity for these *BAG3* variants most likely affects the resistance against John Cunningham virus (JCV) in the index patient. Neither of the two variants is present in the unaffected brother.](ACN3-3-226-g003){#acn3279-fig-0003}

Discussion {#acn3279-sec-0008}
==========

Although rare, similar cases of PML in apparently immunocompetent individuals have been reported.[4](#acn3279-bib-0004){ref-type="ref"}, [11](#acn3279-bib-0011){ref-type="ref"}, [12](#acn3279-bib-0012){ref-type="ref"} Due to its variable demographics, presenting symptoms, and prognosis, the diagnosis of PML remains a challenge, especially in apparently immunocompetent individuals. The diagnosis can be strengthened by a positive PCR for JCV in the CSF, which has a high sensitivity and specificity. However, the severity of the immunosuppression seems to determine the accuracy of the available tests, as is illustrated by the low JCV DNA copy numbers in the CSF of highly active anti‐retroviral therapy treated (HAART) HIV patients, as well as in nearly half of the multiple sclerosis patients treated with the monoclonal antibody natalizumab who were diagnosed with PML.[13](#acn3279-bib-0013){ref-type="ref"}, [14](#acn3279-bib-0014){ref-type="ref"}, [15](#acn3279-bib-0015){ref-type="ref"} Moreover, JCV PCR in CSF of PML cases with occult, minimal, or no detected immune suppression was often found negative.[4](#acn3279-bib-0004){ref-type="ref"} Also, substantial variability exists with regard to detection levels and consistency between laboratories even in testing the same sample set. If clinical suspicion remains high and JCV PCR in CSF is negative, a brain biopsy should therefore be performed. It is important to realize that JCV DNA is widespread in the brain of healthy adults and that the viral DNA load seems to increase in immunosuppresive conditions, as was observed in an autopsy study in HIV patients without PML (no clinical symptoms during life and no neuropathologic evidence of PML).[16](#acn3279-bib-0016){ref-type="ref"} Expression of viral proteins, which can be demonstrated by immunohistochemistry is, however, considered a pathognomonic sign of PML. In our case, viral DNA was found in the biopsy material, however, expression of viral proteins was not observed. Therefore, PML was initially not considered the most likely diagnosis in this immunocompetent patient.

Identifying factors that determine JCV reactivation in an immunocompetent patient will profoundly contribute to the understanding of pathogenesis of PML.[17](#acn3279-bib-0017){ref-type="ref"} Moreover, it might contribute to novel treatment options. IFN*γ* is an important cytokine in human antiviral cellular immune response. The observation that the IFN*γ* response in our patient was decreased after stimulation with PolyI:C, a synthetic TLR3 ligand used to simulate viral infections, suggests a specific deficit in the cellular antiviral immune response. Interestingly, IFN*γ* was recently reported to inhibit expression of JCV T‐antigen, the major viral regulatory protein.[18](#acn3279-bib-0018){ref-type="ref"} In addition, this study showed a significant decrease of JCV DNA copies in cells upon IFN*γ* treatment in vitro. The observed IFN*γ* deficit is most likely an important factor in the pathogenesis of PML in our patient; whole exome sequencing was performed in order to identify any genetic defects that could contribute to this deficit. Compound heterozygous *BAG3* variants in our patient are worthy candidates for increased susceptibility to PML as *BAG3* is implicated in autophagy and apoptosis through intracellular protein control. It was previously shown that overexpression of *BAG3* results in a decrease of the JCV replication, and reduced T‐antigen expression through autophagic degradation, thereby controlling the JCV lytic cycle and its interaction with host cells.[9](#acn3279-bib-0009){ref-type="ref"} Although it remains speculative, the observed genetic variants in *BAG3* might compromise the response against JCV T‐antigen in our patient, leading to insufficient IFN*γ* production, and subsequently PML.

Obviously this case report has several limitations and the results should be interpreted with caution. First, although the segregation analysis showed an autosomal recessive inheritance, the family is rather small, which makes the pathogenicity uncertain. Validating our findings in other cases is therefore crucial, however, due to the rarity of PML in apparent immunocompetent patients this remains extremely challenging. We took up this challenge and performed genetic testing for *BAG3* variants in two previously reported apparent immunocompetent PML cases.[11](#acn3279-bib-0011){ref-type="ref"}, [12](#acn3279-bib-0012){ref-type="ref"} Unfortunately, no *BAG3* variants were discovered in these patients. Given the number of factors suggested to be involved in the reactivation of JCV in order to develop PML and therefore increased heterogeneity between these patients, this might not be surprising.[17](#acn3279-bib-0017){ref-type="ref"}, [19](#acn3279-bib-0019){ref-type="ref"} In addition to the genetic variants in *BAG3*, we also provide evidence for low INF*γ* levels in this case. However, a possible association between the IFN*γ* deficit and the *BAG3* variants remains to be shown.

This case report shows that specific defects in the IFN*γ* production upon stimulation may be present in PML patients without known immune deficits. Patients suspected of PML without immunosuppression should, in addition to regular immunologic screening, be tested for IFN*γ* deficiency to confirm our findings. In these conditions treatment with IFN*γ* might potentially be an option for PML, similar to other conditions treated with recombinant IFN*γ*.[20](#acn3279-bib-0020){ref-type="ref"}
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